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Update on biological, social and economical aspect of
Alzheimer's diasease and other dementia*
DEMENTIA SYNDROME: DEFINITION,
CLASSIFICATION, EPIDEMIOLOGY
Dementia is tipycally late-onset clinical condition with most casesdeveloping in people aged 65 and more. It is characterized by a
progressive decline in memory and other cognitive abilities, including
at least one of the following:
• an ability to generate coherent speech or understand spoken or
written language
• an ability to recognize or identify objects
• an ability to execute motor activities, assuming intact motor func-
tion
• an ability to think abstractly, make sound judgments and plans
and perform complex tasks.
Alzheimer's disease is the most common cause of dementia, ac-
counting for approximately 2/3 of all cases of dementia. The rest in-
cludes, in almost equal proportions, vascular dementia and other types
of dementia (Table 1). Although different types of dementia can be dis-
tinguished according to specific symptom patterns and microscopic
brain abnormalities (on autopsy), there is a large range of overlap be-
tween them. This can further be complicated by coexisting medical
conditions, such as depression and disorders of vascular origin, fre-
quently occurring in people at advanced age. So, pure forms of demen-
tia rarely exist and most cases reflect mixed underlying clinical condi-
tions, but all result in progressive damaging of brain cells and more or
less unique pathologic features.
It is estimated that dementia affects more than 35 million people
worldwide. This figure is predicted to be tripled in the forthcoming de-
cades due to the aging of population. This will increase the financial
burden for healthcare systems and communities, because dementia
syndrome is, in its severe stage, characterized by progressive loss of
functional independence. A need for increasing levels of supervision
and personal care and possibly for nursing home placement, and ulti-
mately, death in 4–10 years after the diagnosis is the natural course of a
dementia syndrome (Figure 1). Whereas other major causes of death,
such as heart disease, stroke, breast cancer and prostate cancer, are on
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the decrease, death attributed to Alzheimer's disease in-
creases dramatically (47% increase between 2000 and
2006). This is why Alzheimer's disease and other demen-
tia today represent one of the most urgent medical, social
and economic challenges.
ELUCIDATING THE PATHOPHYSIOLOGY
OF ALZHEIMER'S DISEASE IS THE BASIS
FOR DEVELOPING DISEASE MODIFYING
TREATMENTS
Alois Alzheimer gave the first description of Alzhei-
mer's dementia in the early 1900s. Almost a century has
gone without considerable advances with respect to treat-
ment of this disorder. Available medications produce
only temporary relief of symptoms, but are not able to
stop disease progression (Table 2). In the last two de-
cades, an important step has been made in understand-
ing molecular cascades underlying the neuropathology
of Alzheimer's disease (AD). These advances have pro-
vided the framework for the recent breakthrough in new
therapeutic strategies that are believed to have a potential
to change the course of the disease (Table 2).
AD is neuropathologically characterized by the depo-
sition of senile plaques and neurofibrillary tangles and
neuronal cell degeneration and loss. Two main hypothe-
ses try to explain the pathogenesis of AD: the cholinergic
hypothesis and the Ab-cascade hypothesis. The majority of
drugs, currently licensed or still under the investigation,
have been manufactured according to these hypotheses
(Table 2).
The cholinergic hypothesis states that selective loss of
cholinergic function (associated with the action of the
neurotransmitter acetylcholine) in the brain is the cause
of cognitive decline in AD. This has been supported by a
382 Period biol, Vol 111, No 3, 2009.
Ljiljana Majnari}-Trtica Alzheimer's disease
TABLE 1
Common types of dementia and their typical characteristics
(source: Alzheimer's Association / Alzheimer's & Dementia 5 (2009) 234-270)
Type of dementia Characteristics
Alzheimer's disease Most common type of dementia, accounting for 60%-80% of cases
Clinical course: steady and progressive loss of memory and cognitive faculties, including language,
visuospatial skills and judgement
Early symptoms: difficulties in remembering names and recent events, apathy and depression
Later symptoms: impaired judgment, disorientation, confusion, behavior changes, trouble in
speaking, swallowing and walking
Neuropathology: extracellular Ab-amyloid deposits (senile plaques) and intracellular strands com-
posed of tau-proteins (tangles)
Radiographic features: temporal and hippocampal cortex atrophy
Vascular cognitive impairment /
Vascular dementia
The second most common type of dementia, also known as multi-infarct or post-stroke dementia
Clinical course: highly variable and fluctuating, a stepwise decline of cognitive faculties, relatively
perserved memory
Radiographic features: evidence of an ischemic lesion, white matter damage, microinfarction
Mixed dementia Characterized by the presence of the hallmark abnormalities of Alzheimer's and another type of de-
mentia, most commonly vascular dementia, but also other types, such as dementia with Lewy bodies
Dementia with Lewy bodies Clinical characteristics: similar to Alzheimer's disease, including problems with memory and
judgment and behavior changes, cognitive symptoms may fluctuate daily
Visual hallucinations, muscle rigidity and tremor are common
Neuropathology: Lewy bodies (abmormal deposits of the protein a-synuclein, inside nerve cells)
Parkinson's dementia Many patients with Parkinson's disease develop dementia in the later stages of the disease
Neuropathology: hallmark Lewy bodies
Frontotemporal dementia Typical localization in the front and side regions of the brain (one type is Pick's disease)
Clinical symptoms: changes in personality and behavior and difficulties with language
Creutzfeldt-Jakob disease Rapidly fatal disorder
Clinical symptoms: impaired memory, coordination, behavior changes
Variants are caused by consumption of products from cattle affected by mad cow disease, caused by
the misfolding of prion protein throughout the brain
Normal pressure hydrocephalus Caused by the retention of fluid in the brain
Can sometimes be corrected with surgicall installation of a shunt in the brain to drain excess fluid
Clinical symtoms: difficulties in walking, impaired memory, inability to control urine
number of experiments indicating reduced synthesis,
impaired transport and disrupted receptor signaling of
acetylcholine, accompanied with selective loss of choli-
nergic neurons and reduced density of acetylcholine re-
ceptors. Currently approved symptomatic drugs for the
treatment of AD are acetylcholinesterase-inhibitors which
act in this way to slowdown the breakdown of the neuro-
transmitter acetylcholine, thereby prolonging its life and
increasing its amount in the brain.
The Ab cascade hypothesis advocates the statement that
senile plaques and other neurodegenerative changes in
Alzheimer's disease develop as the result of the accumu-
lation of b-Amyloid (Ab) peptides in the brain (Figure 2).
Ab peptides are fragments, 39-43 amino acid residues
in length, generated by cleavage from the Amyloid Pre-
cursor Protein (APP) – normal component of cellular
membrane (Figure 2). Two enzymes, b-secretase and
g-secretase, have been identified as essential for the gen-
eration of these fragments, important because of their
ability to aggregate. Only a small amount of APP is nor-
mally processed in this manner, while APP is predomi-
nantly processed by a-secretase, producing non-amy-
loidogenic APP a fragments (Figure 2).
Ab peptides, particularly Ab42, assembly into fibrillar
aggregates on the basis of their conformational changes.
Their accumulation in the brain is an early event during
the course of AD, preceding the neurofibrillary tangles
formation and the appearance of clinical symptoms.
This is the consequence of either their enhanced produc-
tion or/and diminished clearance. Exact knowledge
about mechanisms involved in the amyloidogenic path-
way has important implications for identification of tar-
get points for therapeutic research.
The Ab hypothesis has lost on popularity upon obser-
vations that Ab deposits poorly correlate with neuronal
cell death and the severity of clinical symptoms. How-
ever, recent findings strongly argue in favor of the
amyloidogenic hypothesis and its potential to provide an
explanation of the mechanisms of neurodegeneration.
These new findings include the identification of soluble,
diffusible oligomeric forms of Ab peptides, found to be
highly neurotoxic. This opens a new avenue for treat-
ment research – that aimed at searching for inhibitors of
receptors which mediate Ab trafficking and toxicity.
Neurofibrillary tangles, another neuropathological
hallmark of AD, are likely to be more relevant than Ab
peptides in mediating neuronal cell death. Therefore, in-
terruption of cascades involved in tangle formation is
likely to be more promising as a disease modifying treat-
ment.
Tangles are intracellularry accumulated aberrantly
folded, tau proteins. In physiologic conditions, tau is a
soluble protein that normally promotes microtubular
stability. Normal microtubule function is essential for
axonal integrity and connectivity and, finally, for provid-
ing the plasticity of synapses.
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TABLE 2
Alzheimer's disease medications approved for use by the US Food and Drug Administration (FDA) or currently in phase II or
phase III clinical trials.
Symptomatic drugs, cholinesterase inhibitors,





Memantine (Namenda, Axura, Ebixa, Memox), 2003
In phase II and phase III clinical trials
The first antiamyloid drugs, failed in phase III
Tramiprosate – Ab-binding compound, amyloid aggregation inhibitor
Tarenflurbil – modulator of the g-secretase activity, reducing generation of Ab amyloid peptides
Currently in clinical trials
Bapineuzumab – monoclonal amino terminus-specific anti-amyloid antibody
Rember (methylene blue) – the first anti-tangle medication
Dimebon – neuroprotection, inhibition of the brain cell death
(multiple mechanisms of action: blocking the action of Ab amyloid peptides and calcium-channels, modulating the activity of
AMPA and NMDA glutamate receptors, blocking mitochondrial pores and modulating a number of other receptors)
Flurizan – a selective Ab42-lowering agent
LY450139 – a g-secretase inhibitor
AN1792 – a vaccine
Cerebrolysin – neurotrophic factor (similar to Nerve Growth Factor), acts as signal molecule with pleiotropic effects at the cellular
level, including: neuroprotection, neurogenesis and neuroplasticity
Posttranslational modifications of tau by mechanisms
such as hyperphosphorylation (due to high levels of serine
and threonine residues) lead to conformational changes
of a native protein. In this way, tau becomes resistant to
degradation, loses its physiological functions and gains
toxic abilities, actively promoting neuroinflammation and
neuronal cell death (Figure 2).
According to these findings, the main targets for ther-
apeutic interventions may be affected through the inhi-
bition of the activity of protein kinases - enzymes in-
cluded in phosphorylation of tau. Another approach is
microtubule stabilizing drugs. Efforts are also focused on
modulating the intracellular ubiqutin system responsi-
ble for refolding of aberrantly folded proteins.
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Figure 2. Senile plaques, composed of aggregatedAb amyloid proteins, and neurofibrillary tangles (misfolded tau proteins), are the neuropathological
hallmarks of Alzheimer's disease. (source: promoting materials)
Figure 1. The spectrum of therapeutics for Alzheimer's disease. (source: promoting materials)
One of the most promising strategy for the treatment
of AD, currently under evaluation in clinical trials, is
immunotherapy. Either by passive immunotherapy (mo-
noclonal antibodies recognizing particular epitopes on
Ab or phosphorylated tau molecules, administered intra-
venously), or by active immunotherapy (vaccines con-
taining Ab or phospho-tau derivatives in combination
with strong adjuvants, capable to induce specific antibody
response) – the mechanism of action is the same – selective
clearance of pathological neuroproteins from the brain,
followed by the improvements in clinical symptoms.
Upon binding Ab or phospho-tau fragments in the
blood, specific antibodies (administered passively or ac-
tively produced in the body) initiate their clearance, us-
ing one of the following mechanisms: stimulated phago-
cytosis, ubiquitin independent intracellular degradation
via lysosomes, or ubiqutin dependent intracellular deg-
radation. This is followed by the removal of pathological
aggregates from the brain to balance the blood levels of
neuropeptides.
Alternatively, either passively administered, or acti-
vely produced in the peripheral immune system, specific
antibodies can enter the CNS directly, passing the blood-
-brain barrier by actually both, receptor-mediated trans-
port and passive diffusion. This is likely to be the pre-
dominant way of immune-mediated neuropeptide
clearance. Actually, in a disease state, especially in AD,
the permeability of the blood-brain barrier is increased,
allowing specific antibodies to pass by.
As a curiosity of an immune-based therapy, antibodies
with chaperon-like activities have recently been manu-
factured. These antibodies, by binding to specific sites on
misfolded tau molecules, are capable to reverse their con-
formation in forms more prone for degradation via
ubiquitin dependent pathway.
Ab and tau pathologic pathways have been shown to
interact with each other in a synergistic way. It is sug-
gested, therefore, that reaching both by therapy should
be more effective. This may be achieved by employing
multiple targets treatments, or by the treatment focused
on a single molecular target, but sharing multiple patho-
genetic pathways.
The enzyme glycogen synthase kinase-3 (GSK-3),
identified long time ago as an actor in the insulin signal-
ing pathway, is one of such promising single-molecular
targets for the treatment of AD, capable to exert multiple
therapeutic effects. It has been shown that increased ac-
tivity of this enzyme is associated with both tau hyper-
phosphorylation and increased Ab peptide generation.
Based on these findings, intense research of GSK-3 in-
hibitors is now underway.
Many other molecular pathways underlying neuro-
degenerative processes are currently under investigation,
suggesting novel therapeutic approaches. For example,
the Metals Hypothesis states that altered metabolism of
endogenous brain metals, such as zinc, copper, or cal-
cium, is involved in neurodegenerative processes. Based
on this hypothesis, metal chelators are new candidate
drugs for the treatment of AD.
Furthermore, it is well known that hypertension and
atherosclerotic vascular disease reduce brain perfusion
and may precipitate chronic ischemic conditions associ-
ated with cognitive impairments. Although a distinct dif-
ference exists between vascular type of dementia and AD
regarding clinical symptoms and neuropathologic chan-
ges, a large body of evidence suggests that convergent
processes are included in the progression of both cardio-
vascular and neurodegenerative diseases. Actually, the
same risk factors and dysregulated molecular mecha-
nisms, such as oxidative stress, hyperhomocysteinemia,
inflammation, reduced glucose metabolism and mito-
chondrial abnormalities, already confirmed to be included
in cardiovascular pathology, are likely to have a potential
to initiate and/or strengthen the progression of neurode-
generative processes.
Related to this, many clinical studies are currently be-
ing conducted with the aim to evaluate the effects of
antioxidative drugs (e.g. vitamins C and E, selegiline,
a-tocopherol and plant flavonoids), antiinflammatory
drugs (e.g. naproxen, rofecoxib, Ginkgo biloba extract),
B-vitamin supplementation (to cure hyperhomocyste-
inemia) and some specific agents interfering with in-
creased oxidative stress and impaired glucose metabolism,
such as inhibitors of receptors for advanced glycation end
products (RAGE).
There is some evidence that classical cardiovascular
drugs, including statins and drugs affecting the renin an-
giotensin system, can also elicit positive therapeutic ef-
fects on the course of AD.
Long-standing paradigm that neurons do not regen-
erate during adulthood does not hold any more, as neu-
ronal stem cells have been isolated from adult brain.
New technologies are currently under investigation to al-
low using stem cells in neuroplacement therapy.
Nerve growth factor has received an attention as a po-
tential therapeutic agent for AD due to its selective neu-
rotropic activities on the brain cholinergic system. The
main obstacles for its clinical use are the need for its di-
rect neurosurgical delivery to the brain and considerable
toxic side-effects. It is believed that this might be over-
come by using small molecule approach (neurotrophins).
This approach is based on using simple chemical com-
pounds which are able to pass the blood-brain barrier
upon systemic administration and to activate the Nerve
Growth Factor signaling pathway at specific sites.
Only five drugs are currently approved by the Ameri-
can Food and Drug Administration (FDA) for the treat-
ment of AD (Table 2).
In contrast, over a hundred disease modifying treat-
ments are under clinical evaluation (Table 2). Disease
modifying therapeutics are expected to slow disease pro-
gression rate by at least 25%–30%, to interfere with patho-
physiologic mechanisms and to show a long-lasting (at
least 18 months) beneficial effects on clinical symptoms.
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However, many clinical trials have failed to show clear
clinical benefits, or have been halted because of adverse ef-
fects. Groups of experts consider the methodological is-
sues to find reasonable explanation for such results. Dis-
cussion is focused on study design, outcome measures, the
use of biomarkers in monitoring disease progression and
an appropriate target population selection. Special atten-
tion is paid on establishing criteria for early diagnosis.
This may have implications on the success of clinical tri-
als, as the evidence obtained until now suggests that many
therapeutic strategies could be beneficial if administered
in the early or non-symptomatic phase of a disease.
DIAGNOSIS, THE CONCEPT OF MILD
COGNITIVE IMPAIRMENT (MCI),
BIOMARKERS
The diagnosis of AD is based on the presence of de-
mentia and the exclusion of other disorders with similar
symptoms. It is especially important to identify coexist-
ing conditions, e.g. depression, use of some medications,
the thyroid gland abnormality, vitamin B12 or folate defi-
ciency and cardiovascular disease and its risk factors
which are all potentially treatable.
Wherever it is possible, brain-imaging scanning, CT or
MRI, are recommended, to exclude tumors, or thrombus,
or microinfarction and to support the diagnosis of AD.
Neuroimaging findings, typical for AD, include some de-
gree of atrophy in memory-related cortical regions of the
brain, including temporal and hippocampal ones.
An onset of overt dementia is not a discrete event.
Rather, there is a gradually changing continuum from
healthy cognition to impaired cognition and dementia.
Therefore, neuropsychological testing is needed to sup-
port the diagnosis, by assessing the types and the severity
of cognitive symptoms. One of the most commonly used
tests for screening in the general population is MMSE
(Mini Mental State Examination).
The accuracy of clinical diagnosis varies from 50% (in
the primary health care setting) to over 90% (in special-
ized clinics). The diagnosis can only be confirmed by
autopsy.
Experiences from the clinical trials investigating no-
vel pharmaceutical approaches show that the earlier a
disease is diagnosed – the earlier the treatment can start –
the more likely are positive effects of treatment on pre-
venting progressive neuronal loss. To recognize persons
at high risk for developing dementia (most commonly of
Alzheimer's type), the concept of Mild Cognitive Impair-
ment (MCI) has been introduced. MCI is defined as a
stage of cognitive impairment severe enough to be no-
ticed by others and registered on cognitive tests, but not
enough to interfere with daily life (MMSE>25) (Figure
1). It is estimated that about 10%-20% of people aged 65
years and older have MCI. A significant proportion of
them, but not all, will develop clinically overt dementia
in the following several years. The question of great con-
cern is how to establish indicators of progression from
MCI to dementia.
Available neuropsychologic tests, including MMSE,
show weak positive predicting accuracy. Efforts are there-
fore focused on searching for more specific options of
neuropsychologic testing. Computer-assisted cognitive
test batteries are also in progress for use in both clinical tri-
als and nursing homes. Advantages of computer-assisted
testing in monitoring cognitive changes, in comparison
with the traditional one using paper and pencil, are more
comprehensive and more sensitive outcome measures.
On the other side, the challenge is to develop compre-
hensive cognitive tests with respect to cultural diversity,
suitable for use in cross cultural studies. This is impor-
tant because it has been observed that the high iliteracy
rate and low educational level in developing countries
may result in the screening of cognitively normal elderly
to be positive for dementia.
An area of active investigation are also biomarkers,
such as neuroimaging techniques and cerebrospinal fluid
(CSF) biomarkers. Particularly biomarkers indicating
b-amyloid depositions in the brain, such as PET (posi-
tron emission tomography) scanning and CSF measure-
ment of Ab are thought to have the potential to identify
asymtomatic or very mildly symptomatic individuals.
This approach is based on the findings that amyloid de-
positions precede clinical symptoms by many years. The
problem is that pathological processes in AD are not un-
derstood well enough to be directly measured with bio-
markers or imaging outcomes and do not well correlate
with clinical outcomes. For example, amyloid deposi-
tions in the brain can be found at autopsy of older people
not showing symptoms of cognitive impairments during
life. Expert groups therefore suggest that the simulta-
neous evaluation of cognitive changes, brain volume (of
hippocampus region) and CSF biomarkers should be
used in predicting which person has the greatest chance
to develop dementia in a near future.
Sophisticated new neuroimaging technologies, such
as PiB (Pittsburg Compound) – PET, PET scanners
equipped with the amyloid binding radiotracers, or FDG
(fluorodeoxyglucose) – PET, PET scanners indicating
impaired glucose metabolism in particular regions of the
brain, have recently been established. Technological ad-
vances are expected to improve the feasibility of brain im-
aging in asymtomatic stage of AD and to allow functional
neuroimaging. The latter means comparing changes in
brain metabolism and patterns of neuronal activation
with the type of mental activities, both in health and dis-
ease state.
The levels of neuropeptides in both CSF and blood
have been shown to correlate with the extent of brain am-
yloid deposition. To avoid measurement by more aggres-
sive lumbal puncture and to facilitate biomarker research
in a more simple and patient-friendy approach, a num-
ber of molecular diagnostic techniques are under devel-
opment using peripheral blood as a sample material.
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Except for diagnostic purposes, biomarkers are valu-
able in selecting subjects for clinical trials as it has been
shown that patients with AD differ among themselves
regarding subtle pathobiologic characteristics, response
to treatment and clinical course.
An emerging area of biomarker application is shorten-
ing phase III clinical trials during drug investigation.
Actually, large and long-term studies should be conducted
to show the effect of medication on slowing clinical pro-
gression or delay the time of diagnosis. In this situation,
biomarkers could be validated as a surrogate endpoint.
Difficulties in establishing biomarkers for tracking
disease progression can arise from the observations that a
large number of non-demented elderly individuals have
brain amyloid at autopsy. In addition, some of the people
with subtle memory symptoms can revert to the healthy,
some of them remain the same, and some proceed to de-
mentia. There is a poor correlation between clinical stage
and the type of dementia and the patterns of neuropatho-
logic and neuroimaging changes. For this reason, joined
international initiatives in the form of large longitudinal
studies, are underway with the aim to provide more
clearer answers about which individuals are likely to de-
velop AD and when it is likely to happen. One of the
most respectable and best funded initiatives is ADNI




Alzheimer's dementia is considered as a chronic aging
disease and is distinguished from normal aging. Most
cases are aged 65 years or older (a late-onset disease), al-
though an overt dementia in some cases appears under
the age of 65 years (younger-onset or early-onset dis-
ease). These are predominantly cases caused by rare ge-
netic mutations, linked to amyloidogenic and tau patho-
logic pathways.
Only one susceptibility gene for common, late-onset
AD has been identified until now. This is apolipoprotein
Ee4 (APOEe4), one of the three variants of the APOE4
gene whose protein products normally serve as carriers
for circulating cholesterol. Over the last few years, large
scale Genome Wide Studies have been undertaken to
identify new susceptibility genes. However, it is likely
that there will not be any novel single gene responsible
for the development of AD, but rather multiple gene al-
terations characterize the disease. Based on these obser-
vations, gene-expression profiling techniques, performed
on blood samples, have been emerging. This is thought
to be a promising method for screening of the general
population for the early diagnosis of AD.
Results of epidemiologic studies are convergent to
those from studying genetics, indicating that AD, like
other common aging diseases, is probably a result of
multiple environmental factors acting on DNA sequence
through epigenetic mechanisms. Lifestyle and cardio-
vascular risk factors, including high blood cholesterol,
diabetes mellitus, hypertension, high blood homocystei-
ne levels and low physical activity, have also been identi-
fied as risk factors for AD.
The great impact of environmental and socioecono-
mic factors on the expression of AD is illustrated by the
fact that the variable »fewer years of education« signifi-
cantly increases the risk of developing dementia at older
age. Fewer years of education may be a surrogate marker
for more complex socioeconomic factors affecting access
to education. Also, this factor may reflect the level of oc-
cupational activities and lifestyle conditions associated
with mental and physical health.
Cognitive Reserve Hypothesis (Stern, 2002) could pro-
vide a reasonable explanation for this association. This
hypothesis has been established to explain observations
that a number of patients with extensive brain neuro-
pathologic changes are able to perform to a considerably
higher level in clinical and neuropsychological examina-
tions. The Cognitive Reserve Hypothesis states that an
ability to cope with the brain pathology and to maintain
normal neuropsychological performance is likely to de-
pend on the capacity to recruit alternative neuronal net-
works. Surrogate markers for this capacity, termed cogni-
tive reserve, have been identified and include the level of
education and occupational activities, premorbid intelli-
gence quotient and an overall cognitive and mental-sti-
mulating activities.
VASCULAR COGNITIVE IMPAIRMENT
The brain is one of the most highly vascularized or-
gan in the body. For this reason, cardiovascular disease
and its risk factors affect also the brain and influence the
risk for developing cognitive impairment and dementia.
Neuropathologic changes associated with vascular de-
mentia generally differ from that in AD (mainly caused
by neurodegenerative processes) and include large- and
small-vessel disease, white matter lesion, micro-infarc-
tion and micro-hemorrhage.
However, there is a large degree of overlapping be-
tween AD and vascular dementia, best demonstrated in
the form of mixed dementia (Table 1). The main pro-
posed mechanisms by which vascular dementia and its
risk factors accelerate brain atrophy are cerebral hypo-
perfusion, increased oxydative stress and reduced glu-
cose metabolism. There is a growing body of evidence
suggesting that cardiovascular risk factors may, by shar-
ing molecular targets, affect both vascular and neurode-
generative pathogenetic pathways.
The relationship between vascular risk factors, cogni-
tive impairment and dementia risk is an emerging field of
research, especially with respect to the early phase of cog-
nitive impairment and subclinical cardiovascular disease.
The question that needs a definite answer is whether
prevention/reversal of cognitive symptoms may be
achieved through vascular risk factor management and
treatment. This is of particular interest because earlier
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detection of cardiovascular risk factors and advances in
therapy of cardiovascular diseases in the last decades, in-
cluding the widespread use of new drugs such as statins
and ACE-inhibitors, have taken part in the decline of
mortality and the increase in the prevalence of these dis-
orders. How these two opposite trends, increasing preva-
lence, in parallel with improvements in the treatment of
cardiovascular disease and its risk factors, can affect the
rates of dementia – is unclear at the moment.
In general, evidence suggests that clear separation be-
tween neurodegenerative and vascular pathobiology is
not possible. The occurrence and the patterns of cogni-
tive impairments and dementia are likely to be influ-
enced by the existence of vascular diseases (including
type, severity and duration), other co-existing conditions
and underlying vulnerability, including age, education,
positive family history of dementia and genetics. It is pre-
sumed, therefore, that one single strategy is not enough
to prevent/cure cognitive disorders, but rather a combi-
nation of strategies will be needed, including lifestyle
changes, multi-target medications, counselling, support
groups and occupational therapies.
SOCIAL AND ECONOMICAL IMPACT OF
ALZHEIMER'S DISEASE AND OTHER
DEMENTIA
Alzheimer's disease and other dementia are devastat-
ing for patients and exhausting for those who care for de-
mented people. These are, in most cases, family mem-
bers. They often suffer emotional stress and are under
the pressure of financial burden. Except of caregiving-re-
lated expenses, the financial loss to caregivers includes
the reduction of their work hours or taking time off be-
cause of caregiving duties. Moreover, about one-third of
caregives have symptoms of depression and are more
likely to get hypertension and coronary artery disease.
Some demented patients require long-term care ser-
vices, including nursing home care, mostly because of
the exhaustion or inability of family members to provide
care. The costs of long-term care place a burden on pri-
vate financial resources and have a substantial impact on
the healthcare system.
The capacity of long-term care institutions and the
extent of the network of formal services for the elderly
and demented persons depend on the healthcare system
and the economic power of the state. Even in developed
countries, a huge lack of health care workers and profes-
sionals with training in geriatrics can be observed. Health
care staffing and development of support programs will
be a challenge in the future as the number of people aged
65 and older is expected to grow.
It is estimated that pharmacological treatments and
caregiver interventions, if started early, delay the need for
nursing home placement and reduce the costs of caregiv-
ing. However, many patients with dementia are not diag-
nosed at all or are diagnosed at late stages of the disease.
This can be attributed to several factors, including: low
public sensibility for the problem, the prevailing fatalist
perception that nothng can be done with such patients,
the lack of physicians' knowledge abut dementing ill-
nesses, the absence of recommendations for broader cog-
nitive screening, only limited effects of available medical
treatments and the absence of networked support pro-
grams.
Current efforts of the research teams to make a sub-
stantial therapeutic breakthrough in neurodegenerative
diseases, along with the progress in imaging techniques,
biomarkers and other techniques aimed at improving
early diagnosis, are axpected to drive future advances.
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